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Abstract 
Perfluorochemicals (PFCs) constitute one class of artificial oxygen carriers that are being 
produced completely synthetically. One formulation that has been evaluated extensively in 
clinical trials is a 60% w/v perflubron-based emulsion. Efficacy and safety of this perflubron 
emulsion was evaluated in a Phase 2 and a large prospective randomized Phase 3 multicenter 
European study, which collectively included a total of 639 patients. Perflubron emulsion was 
highly successful in improving organ function, reversing physiologic transfusion triggers and in 
reducing the need for allogeneic blood transfusions. There were no major safety issues.  
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Patient Blood Management (PBM)(17-19, 22) has been developed to avoid the adverse effects of 
preoperative anemia(11), preoperative iron deficiency (10), high blood loss (12) and the 
transfusion of allogeneic blood products(1, 4, 5, 18)on patient outcome.  
Within the concept of PBM, acute normovolemic hemodilution (ANH) is one of the measures 
contributing to reduce the need for allogeneic blood products (18, 19, 22). The efficacy of mild 
ANH, however, has been challenged (2) and profound ANH exposes the patient to low 
hemoglobin levels that may not be well tolerated by certain patient groups. Therefore, the 
concept of augmented ANH was developed to combine ANH with the administration of an 
artificial oxygen (O2) carrier in order to maintain O2 supply to vulnerable organs during the 
period of minimal Hb(3, 8). Perfluorochemicals (PFCs) constitute one class of artificial oxygen 
carriers with the advantage of being produced completely synthetically(13). The formulation that 
has been evaluated extensively in Western Europe and North America in clinical trials is a 60% 
w/v perflubron-based emulsion originally developed by Alliance Pharmaceutical (San Diego, 
CA), which is a lecithin-stabilized emulsion of perfluorooctyl bromide (C8F17Br) and 
perfluorodecyl bromide (C10F21Br)(7). Efficacy and safety of this perflubron emulsion was first 
evaluated in a Phase 2 study in Europe(20)and subsequently in a large prospective randomized, 
Phase 3 multicenter European study performed in 492non-cardiac surgery patients(21).  
The European Phase 2 study enrolled 147 patients undergoing major orthopedic surgery(20). All 
patients underwent ANH to a Hb of 90 g/L immediately prior to surgery while being ventilated 
with an inspiratory O2 fraction (FiO2) of 0.40. The volume of the autologous blood harvested on 
average was approximately 1000 mL. When reaching a predefined physiologic transfusion 
trigger (Table 1A) patients were randomized to one of four treatment groups, as shown below.  
(A) Re-transfusion of autologous blood (450 mL) harvested during ANH at FiO2 of 0.40 
(B) 450 mL of colloid at FiO2 of 1.0 
(C) 0.9 g perflubron emulsion per kg of body weight with colloid for a total volume of 450 
mL at FiO2 of 1.0 
(D) 1.8 g perflubron emulsion per kg of body weight with colloid for a total volume of 450 
mL at FiO2 of 1.0 
The protocol-defined primary endpoint was the duration of transfusion trigger reversal(20). In 
patients not achieving a transfusion trigger reversal or when reaching a transfusion trigger a 
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second time, one unit (450 mL) of autologous blood was re-transfused. All remaining autologous 
blood was re-transfused at the end of surgery.A Hb < 60 g/L after the first treatment,or a Hb < 80 
g/L at the end of surgery were additional triggers for transfusion for autologous units first, 
followed by transfusion of allogeneic blood transfusions if needed to correct the Hb-based 
trigger. 
High dose perflubron emulsion was the most successful treatment with a duration of transfusion 
trigger reversal of 80 (60 – 100) min (median (confidence interval)), followed by low dose 
perflubron emulsion (59 (40 – 90) min), re-transfusion of autologous blood (55 (30 – 70) min) 
and colloid only administration (30 (27 – 60) min). The duration of transfusion trigger reversal 
was significantly longer (p < 0.05) in both perflubron emulsion groups as compared to the 
colloid group. Furthermore, the duration of transfusion trigger reversal was significantly longer 
(p < 0.05) in the high dose perflubron emulsion group as compared to the autologous blood re-
transfusion group. In addition, the percentage of transfusion trigger reversal was highest with 
high dose perflubron emulsion (97%, p < 0.05 vs. colloid and autologous blood re-transfusion 
groups), followed by low dose perflubron emulsion (82%), colloid only administration (76%) 
and re-transfusion of autologous blood (60%). The success of high-dose perflubron emulsion 
treatment tended to be underestimated. In more than 50% of patients, the true duration of 
transfusion trigger delay was artificially limited because the end of surgery, by 
protocol,mandated reinfusion of ANH blood and this occurred before a true transfusion trigger 
had been reached. This means that the true length of delay from tachycardia, hypotension, 
oxygen demand etc. could well have been considerably longer(20). 
Allogeneic transfusions were similar in all treatment groups. This was to be expected for this 
study, since patients were managed at nearly identical Hb levels by protocol. In addition, the 
additional transfusion triggers of Hb < 60 g/L during the treatment and Hb < 80 g/L at the end of 
surgery virtually precluded a difference in allogeneic blood transfusions. If exclusively 
physiologic transfusion triggers would have been used, patients receiving high dose perflubron 
emulsion would be expected to tolerate lower Hb values; hence, bleeding would have occurred at 
lower Hb levels and thereby reduce red blood cell loss during surgery, which likely would have 
translated into a reduced need for allogeneic blood transfusions. 
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Treatment with perflubron emulsion was well tolerated, incidence of serious as well as all 
adverse events (AEs), and postoperative recovery was similar in all groups. The only difference 
was that on postoperative day 2-4 the platelet count was slightly lower in the high-dose 
perflubron emulsion group than in the other groups. However, the clinical relevance of this 
finding is likely to be minimal since it was not associated with any bleeding complication and 
may even be considered protective given that fact that in this period after major surgery (16) or 
trauma (14, 15) patients show signs of severe hyper-coagulopathy which may be associated with 
thrombotic complications. 
In a subsequent prospective randomized multicenter Phase 3 study (492 patients in 34 centers in 
8 countries),perflubron emulsion was tested in major non-cardiac surgery with an expected blood 
loss of ≥ 20 mL per kilogram of body weight(21). Patients randomized to the perflubron 
emulsion group were preoperatively hemodiluted to a target Hb of 80±5 g/L, and then received 
the first dose of perflubron emulsion (1.8 g per kg of body weight). When Hb reached 65±5 g/L, 
a second dose of perflubron emulsion (0.9 g per kg of body weight) was administered and RBC 
transfusion were then given as needed, eitherwhen Hb decreased to < 55±5 g/L or at protocol-
defined physiologic transfusion triggers (Table 1B). Patients randomized into the control group 
were treated according to standard of care, which did not include preoperative hemodilution. 
During surgery these patients were transfused at a Hb < 80±5 g/L or at protocol-defined 
physiologic transfusion triggers (Table 1B). Postoperatively, a Hb transfusion trigger of 85±5 
g/L was used in both groups. The primary outcome was the number of allogeneic and 
preoperative autologous units transfused and the percentage of patients avoiding any RBC 
transfusion(21). 
More patients in the perflubron emulsion group avoided any RBC transfusion at 24h (53% vs. 
43%, p=0.05) and fewer RBC transfusions were given (0 vs. 1 unit, p=0.013). At hospital 
discharge, these differences were still present but were no longer statistically different. However, 
in the protocol-defined target population, i.e.,in patients with a blood loss of ≥ 20 mL per kg of 
body weight (330 of 492 subjects), significantly more patients in the perflubron emulsion group 
avoided any RBC transfusion until hospital discharge (26% vs. 16%, p<0.05). In addition, the 
number of RBC units transfused was also lower in patients in the perflubron group than in 
control patients (2 vs. 4 units, p< 0.001).Overall, adverse events were similar in both groups, 
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while serious adverse events were more frequent in the perflubron emulsion group (32% vs. 
21%, p<0.05). 
Interestingly, a post-hoc exploratory analysis showed that in patients with a blood loss of ≥ 10 
mL per kg of body weight (424 of 492 subjects), more patients could avoid any RBC transfusion 
when treated with ANH and perflubron emulsion than in control patients with standard of care 
treatment. 
As seen in the previous Phase 2 study(20), postoperative platelet count was significantly lower in 
patients treated by perflubron emulsion for up to 7 days. However, the group mean platelet 
counts never reached a level below 100,000 / l and was not associated with any bleeding 
complications or the need for supplemental treatment with fresh frozen plasma (13% in both 
groups) or platelet transfusion (7 platelet transfusions in each group)(21). This was consistent 
with the Phase 1 study of Leese et al. (9)who found various coagulation tests largely unaffected 
over 14 days in healthy volunteers following treatment with saline and perflubron emulsion at 
1.2 and 1.8 g per kilogram of body weight. 
Taken together, these two studies clearly show that the treatment with preoperative ANH and 
perflubron emulsion can reduce the need for allogeneic blood transfusion significantly in patients 
undergoing major non-cardiac surgery with a minimum blood loss of at least 10 mL per kg of 
body weight. The only consistent side effect observed was a lower platelet count during the first 
7 days. It is very important to state that in both studies, postoperative platelet counts were well 
above 100,000 / l and that no coagulopathic bleeding complications occurred. In fact, a mild 
decrease in postoperative platelet count might even protect against postoperative thrombo-
embolic complications (14-16).  
Besides the use to minimize the need for allogeneic RBC transfusions, perflubron emulsion has 
been evaluated as a potential oxygen therapeutic agent in a number of situations (Table 2) where 
ischemia can compromise tissue oxygenation and lead to potential organ injury and/or 
failure.Many of the preclinical studies performed to support these anti-ischemic indications have 
been published and described in various review articles(6, 7).Collectively, these studies have 
demonstrated that: (1) perflubron emulsion can support tissue oxygenation, (2) the oxygen 
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delivered by the PFC is available to support cellular metabolism at the tissue level, and (3) this 
improved oxygenation status has been shown to result in improved organ function. 
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Table 1: Physiologic transfusion triggers in (A) Study in major orthopedic surgery (n=147) (20) 
and (B) Study in major non-cardiac surgery (n=492) (21). 
 
A – Major orthopedic surgery (n=147) 
Tachycardia: HR > 125% of HR after ANH or HR > 110 bpm 
Hypotension: MAP < 75% of MAP after ANH or MAP ≤ 60 mmHg 
High cardiac output: CO > 150% of CO after ANH 
High O2 extraction: PmvO2 < 38 mmHg 
 
B – Major non-cardiac surgery surgery (n=492) 
Tachycardia: HR > 135% of HR after anesthesia induction or HR > 100 bpm 
Hypotension: MAP < 65% of MAP after anesthesia induction or MAP ≤ 60 
mmHg 
High O2 extraction: PmvO2 < 38 mmHg (if PA catheter inserted) 
ST segment alteration: ST depression > 0.1 mV or elevation > 0.2 mV 
 
HR = heart rate, ANH = acute normovolemic hemodilution, MAP = mean arterial pressure, CO = 
cardiac output, PmvO2 = O2 partial pressure in mixed venous blood, PA catheter = Pulmonary 
artery catheter. 
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Table 2: Potential use of perflubron emulsion outside the paradigm of blood sparing 
and Patient Blood Management. 
 
Urgent need for improved O2 delivery 
Ambulance 
Emergency room 
Jehovah Witness patients 
Bridge to transfusion 
Cardiac ischemia 
CPB 
PCI 
MI 
Cerebral ischemia 
Aneurysm 
Stroke 
CPB 
Gut ischemia 
Intensive care treatment 
Abdominal surgery 
CPB 
Trauma / shock resuscitation 
Sickle cell crisis 
Tumor oxygenation prior to radiation / chemotherapy 
Organ preconditioning for transplantation 
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